Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
09 mai 2024 08h00 HE
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
23 avr. 2024 08h18 HE
|
Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
15 avr. 2024 08h00 HE
|
Optimi Health Corp.
Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
09 avr. 2024 09h13 HE
|
Optimi Health Corp.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
02 avr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
28 mars 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
26 mars 2024 07h30 HE
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 févr. 2024 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
12 févr. 2024 07h00 HE
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video